Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD19/CD22 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology

Next Previous
X
Search
Drug Profile

Anti CD19/CD22 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology

Alternative Names: Anti-CD19/Anti-CD22 CAR-T cell therapy - Hebei Senlang Biotechnology; Senl_H19x22; SL19+22 CAR-T cell therapy - Hebei Senlang Biotechnology

Latest Information Update: 27 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebei Senlang Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies

Most Recent Events

  • 08 Jun 2023 Updated efficacy and adverse events data from a phase I/II clinical trials in Non-Hodgkin's lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 09 Jun 2022 Efficacy and adverse events data from a phase I/II clinical trials in Non-Hodgkin's lymphoma presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 08 Apr 2022 Phase-I clinical trials in Haematological malignancies (Recurrent, Refractory metastatic disease) in China (Parenteral) (NCT05388695)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top